This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (8) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Górski, G. Articles by Noszczyk, W. Search for Related Content PubMed PubMed Citation Articles by Górski, G. Articles by Noszczyk, W. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Deep Vein Thrombosis Hazardous Substances DB HEPARIN Social Bookmarking                         What's this?

Liposomal Heparin Spray: A New Formula in Adjunctive Treatment of Superficial Venous Thrombosis

Department of General and Vascular Surgery, Medical Academy in Warsaw, Poland

Piotr Szopiski, MD

Department of General and Vascular Surgery, Medical Academy in Warsaw, Poland

Jacek Michalak, MD

Department of General and Vascular Surgery, Medical Academy in Warsaw, Poland

Agnieszka Marianowska, MD

Department of General and Vascular Surgery, Medical Academy in Warsaw, Poland

Maciej Borkowski, MD, PhD

Department of Surgery, Medical Academy in Warsaw, Poland

Marcin Geremek, MD

Department of Surgery, Medical Academy in Warsaw, Poland

Marcin Trochimczuk, MD

Department of Surgery, Medical Academy in Warsaw, Poland

Jaroslav Brotánek, MD

II. interní klinika, Fakultní Thomayerova nemocnice s poliklinikou, Prague, Czech Republic

Stanislav Sárník, MD

I. interní-angiokardiologická klinika, Brno, Czech Republic

Jirí Seménka, MD

I. interní-angiokardiologická klinika, Brno, Czech Republic

Dariusz Wilkowski, MD

Medagro International, Warsaw, Poland

Wojciech Noszczyk, MD, PhD

Department of General and Vascular Surgery, Medical Academy in Warsaw, Poland

The objective of this study was to assess the efficacy and safety of liposomal heparin spray—a new formula of topical heparin delivery. This was a randomized, multicenter, controlled open clinical trial with 2 parallel groups. Forty-six outpatients with clinical signs of superficial venous thrombosis (SVT) were treated with either topical liposomal heparin spraygel (LHSG) (Lipohep Forte Spraygel, 4 puffs of 458 IU tid (n=22) or with low-molecular-weight heparin (LMWH) (Clexane 40 mg once a day (n=24), administered subcutaneously (sc). Main outcome measures were efficacy parameters (improvement of local symptoms—pain control and planimetric evaluation of erythema size, duplex Doppler assessment of thrombus regression) and safety parameters (documentation of adverse events, with particular reference to deep vein thrombosis [DVT] by duplex sonography, and patients’ and investigators’ assessment of drug tolerance). Patients’ and investigators’ subjective assessment of efficacy of treatment and change in basic biochemical parameters were defined as secondary outcome measures. Statistical analysis was performed with use of Wilcoxon test, Mann-Whitney U-test and Chi-square test. Regression of SVT-related symptoms, including pain, erythema, and thrombus presence, was shown as comparable in LHSG and LMWH groups. These results were corroborated by efficacy assessment by investigators and patients. Three cases of deep venous thrombosis in heparin spraygel and 1 in heparin sc group were reported. No significant adverse reactions were observed in the spraygel group, but 1 serious allergic reaction was observed in the LMWH group. Tolerance of new formula heparin was assessed as good. Heparin spraygel—a new topical mode of heparin application, seems a promising method of heparin delivery. This initial study has demonstrated comparable efficacy and safety of LHSG and LMWH in local treatment of SVT. These findings should be confirmed by further extensive study that will reach appropriate statistical power to support such conclusion, for despite heparin treatment, significant risk of DVT was demonstrated in both groups.

Angiology, Vol. 56, No. 1, 9-17 (2005)
DOI: 10.1177/000331970505600102


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]

				M.R. Cesarone, G. Belcaro, S. Errichi, U. Cornelli, L. Pellegrini, I. Ruffini, B.M. Errichi, A. Ledda, G. Vinciguerra, A. Ricci, et al. Topical Heparin: New Observations Angiology, April 1, 2007; 58(1S): 16S - 20S. [Abstract] [PDF]

				R. Katzenschlager, A. Ugurlouglu, G. Sipos, I. Bihari, E. B. Anyova, M. Hirschl, M. Maruszynski, W. Noszczyk, Z. Rybak, and A. Cencora Efficacy and Tolerability of Liposomal Heparin Spraygel as an Add-on Treatment in the Management of Superficial Venous Thrombosis Angiology, April 1, 2007; 58(1S): 27S - 35S. [Abstract] [PDF]